(Press-News.org) Vienna, Austria: Results from a phase III clinical trial evaluating a new treatment for breast cancer in post-menopausal women show that the combination of two cancer drugs, everolimus and exemestane, significantly improves bone strength and reduces the chances of cancer spreading (metastasising) in the bone.
Professor Michael Gnant told the eighth European Breast Cancer Conference (EBCC-8) today (Friday) that the latest results from the BOLERO-2 trial would change clinical practice. "These results indicate a new standard of care for women with advanced oestrogen receptor positive breast cancer that is resistant to hormonal therapy," he said.
BOLERO-2 had shown previously that the combination of the two drugs significantly improved outcomes, stopping further tumour growth for nearly 11 months, in a group of patients with a form of breast cancer that is highly resistant to treatment. However, as some anti-cancer drugs are associated with reduced bone mineral density and an increased risk of fractures, it was important to discover whether everolimus and exemestane, used with or after treatment with other drugs such as non-steroidal aromatase inhibitors (e.g. anastrozole), affected bone strength.
Prof Gnant, Co-ordinator of the Comprehensive Cancer Centre at the Medical University of Vienna (Vienna, Austria), and colleagues from several different countries looked at markers for bone turnover and bone resorption (the rate at which bone forms, degrades and renews itself) in the 724 patients enrolled in the trial and randomised to receive either everolimus and exemestane or exemestane alone (the placebo group). The patients had an average age of 62, were from 24 different countries and had been treated previously with aromatase inhibitors. They were enrolled between June 2009 and January 2011, and the researchers assessed three different bone markers at the time of enrolment and after six and twelve weeks.
They found that levels of all three bone markers decreased significantly after six and 12 weeks for women taking everolimus, indicating a low turnover of bone, which improves bone strength and health. After six weeks, bone-specific alkaline phosphatase (BSAP) had dropped by 5.5%, amino-terminal propeptide of type 1 collagen (P1NP) had dropped by 20.4%, and C-terminal cross-linking telopeptide of type I collagen (CTX) had dropped by 6.3%. After 12 weeks, they had decreased by 3.6%, 26.8% and 0.5% respectively. In the placebo group they all increased.
Overall, out of all the women in the trial, only 3% of the women taking everolimus had further bone metastases after 60 days, compared with 6% in the placebo group; in a sub-group of women who were known to have bone metastases at the start of the trial, everolimus halved the rate of further bone metastases, with bone metastases progressing in nearly 4% of these women, compared to 8% in the placebo group. This trend continued for longer than six months. Any bone-related side effects were rare and those that did occur were of a low grade, including bone pain and fractures.
Prof Gnant said: "These results show that the addition of everolimus to exemestane is greatly beneficial to bone health by reducing bone turnover and improving time to bone metastases. Everolimus appears to make it more difficult for metastases to occur and grow in bone.
"In addition to the spectacular effect on outcomes and time to progression, both in bone and elsewhere, improving bone health is an important aspect of giving patients the best possible treatment. We would now recommend everolimus, in addition to exemestane, for all post-menopausal women with hormone-resistant advanced cancer until further progression of their cancer.
"The interesting question we would like to address now is the effect of everolimus in women with early breast cancer, where bone health may be an even more important issue. Currently, clinical trials to investigate this are being designed."
Professor David Cameron, from the University of Edinburgh (Edinburgh, UK), and chair of EBCC-8 said: "This study has already demonstrated that resistance to endocrine therapy can be overcome by using medicine to block the way breast cancer cells escape from endocrine therapy. These new data show that this additional treatment has beneficial effects on bone health, the full implications of which are not yet clear."
The hormone oestrogen promotes the growth of about two thirds of breast cancers, and hormonal therapies such as exemestane are used to treat these hormone receptor-positive breast cancers. However, many breast cancer patients and nearly all patients with advanced breast cancer that has metastasised to other parts of the body become resistant to hormonal therapy. When patients stop responding to hormonal therapy, the benefits from any secondary therapy are limited.
Exemestane is currently used to treat women who have metastatic breast cancer and women whose breast cancer has returned after initial treatment. It is also used to treat women with early breast cancer after they have completed two or three years of treatment with another hormonal therapy, tamoxifen.
Everolimus is an inhibitor of the mTOR protein, which has a number of roles, including regulation of cell growth, proliferation, motility and survival. It is an established treatment for recurrent, advanced kidney cancer and researchers are now looking at its use in other cancers. The BOLERO-2 trial was set up to investigate the efficacy of everolimus, in combination with exemestane, in patients who have become resistant to aromatase inhibitors – drugs that decrease the amount of oestrogen produced and help to slow or reverse the growth of the cancer, but which are also known to have an adverse effect on bone health.
###
Abstract no: 3 LBA, Friday 15.00 hrs, Keynote symposium, Hall D
END
Even in places as seemly well-studied as the national parks of North America, new species are still being discovered. Using ultraviolet light that cause scorpions to fluoresce a ghostly glow, researchers from the University of Nevada, Las Vegas (UNLV) have discovered an intriguing new scorpion in Death Valley National Park. They named the species Wernerius inyoensis, after the Inyo Mountains where it was found. The study was published in the open access journal ZooKeys.
This new species is small, only 16 mm in length. "We almost overlooked this one during the survey" ...
A new and unusual wasp species has been discovered during an expedition to the Indonesian island of Sulawesi.
It was independently also found in the insect collections of the Museum für Naturkunde in Berlin, where it was awaiting discovery since the 1930s, when it had been collected on Sulawesi. The new species is pitch-black, has an enormous body size, and its males have long, sickle-shaped jaws. The findings have now been described in the open access journal ZooKeys.
The species belongs into the digger wasp family, which is a diverse group of wasps with several thousands ...
Realcomm Conference Group will be hosting a webinar on March 29 from 12:30pm to 2:00 pm (ET) to define high performance buildings and discuss the ways in which operation, design and organization of the systems play a key role in this new paradigm. Ryan Allbaugh, CIO of Childress Klein will lead the discussion along with Scott Boehm, Director Vykon Channel, Tridium; Paul Oswald, President, Environmental Systems Inc. (ESI); John Petze, Principal, SkyFoundry; and David Weinerth, EVP Marketing, SCIenergy Inc.
"We're hearing a lot about this topic as smart connected ...
The important changes to the way scientists name new plants that took effect on 1 January 2012 included the fall of the so-called Latin requirement - a stipulation that descriptions or diagnoses of new species had to be in Latin.
The new rules make it possible to take full advantage of an ongoing revolution in how botanists and mycologists verify that a particular species is indeed new to science: Many studies now routinely include the sequencing of short DNA regions that will amplify easily, even when the DNA comes from old specimens.
Such "barcoding" sequences can ...
There is a seemingly endless selection of affordable sedans on the market these days, but none are more appealing to Kelley Blue Book's kbb.com than the 2012 Volkswagen Passat. Kbb.com recently unveiled its 10 Best Sedans Under $25,000 list, placing the all-new Passat at the top. Volkswagen's newest midsize offering is available at any VW dealership and was singled out for its pitch-perfect mix of space, refinement and affordability.
Kbb.com evaluated sedans on typical factors like comfortable ride, handling, fuel efficiency, features and value, but it was sportiness, ...
A study by the Complutense University of Madrid (UCM) into the development of speech about the Civil War on Television Española (Spain's national state owned public television broadcaster) states that from the 70's, public television stopped portraying republicans as national enemies and acknowledged their bravery as combatants.
"In the final years of the dictatorship, in Television Española (TVE) documentaries and news programmes, they began to recognise the merits of the defeated republicans, claiming that they simply had a different stance, and they even had 'love ...
An international team of scientists, including some from Majorca and the Canary Islands, have described a new type of fossil scops owl, the first extinct bird on the archipelago of Madeira (Portugal). Otus mauli, which was also the first nocturnal bird of prey described in the area, lived on land and became extinct as a result of humans arriving on the island.
Twenty years ago, the German researcher Harald Pieper discovered fossil remains of a small nocturnal bird of prey in Madeira, which, until now, had not been studied in depth. The international team of palaeontologists ...
ImageFLEX is an agreement unique to Balreed which allows organisations to produce the images they need on the devices they choose. Within an all-inclusive MPS agreement, clients are not restricted to defined volumes of mono or colour images, or volumes per device.
Balreed's Group Marketing Director Gary Downey said: "The clue is in the title with ImageFLEX. This is a new approach to MPS that overcomes the restrictions and compromises of other managed service offerings in the market. With ImageFLEX our clients will benefit from the UK's most pro-active Managed Print ...
Researchers at the European Congress of Osteoporosis & Osteoarthritis in Bordeaux have presented new data * which shows that the economic burden of fragility fractures in the 27 member states of the European Union far exceeds previous estimates, with hip fractures accounting for around 55% of costs.
The investigators used a population based model to estimate the economic burden of fractures in 2010, using data on facture incidence, costs for pharmaceutical prevention and post-fracture health care, mortality, and population size to estimate total costs. Data for hip, ...
Many buyers generate cash from trading and, rather than it earning only bank interest of, say, 3% use that cash to expand by buying other businesses. On average my team is successfully completing 9 or 10 sales every month.
Start with tax advice and do the numbers
Sellers can, with the right professional advice, pay no more than 10% tax on sale proceeds; a rate that compares favourably to income tax at 50%. So far so good, but work out what you are left with after paying tax. What return will you get on that capital? How does that compare to the income you now get ...
